Watch out AbbVie: Gilead is fast on your heels at the FDA with rival JAK inhibitor filgotinib

Moving fast with what it believes is a blockbuster favorite in a crowded market, Gilead has confidently plotted an NDA filing for filgotinib by the end of the year, setting up a potential 2020 launch in rheumatoid arthritis.